These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31568020)

  • 21. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.
    Schellinger PD; Jansen O; Fiebach JB; Heiland S; Steiner T; Schwab S; Pohlers O; Ryssel H; Sartor K; Hacke W
    Stroke; 2000 Jun; 31(6):1318-28. PubMed ID: 10835451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Emergency Carotid Endarterectomy after Thrombolysis with Intravenous Recombinant Tissue-Type Plasminogen Activator.
    Yamamoto Y; Okazaki T; Yoda K; Tada Y; Nagahiro S
    J Med Invest; 2016; 63(3-4):300-4. PubMed ID: 27644576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local intra-arterial fibrinolysis in acute hemispheric stroke: effect of occlusion type and fibrinolytic agent on recanalization success and neurological outcome.
    Eckert B; Kucinski T; Neumaier-Probst E; Fiehler J; Röther J; Zeumer H
    Cerebrovasc Dis; 2003; 15(4):258-63. PubMed ID: 12686789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction].
    Gao R
    Zhonghua Xin Xue Guan Bing Za Zhi; 1991 Aug; 19(4):228-30, 267-8. PubMed ID: 1813288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction.
    Sun F; Liu H; Fu HX; Zhang S; Qian XD; Li JJ; Zhu YB; Zhang XX; Zhang J; Qiu HP; Kang LL; Hu YJ; Zhao L; Mi YJ; Gao YJ; Dou ZJ; Ma Z
    J Int Med Res; 2020 May; 48(5):300060519895352. PubMed ID: 32357116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stroke outcomes of Japanese patients with major cerebral artery occlusion in the post-alteplase, pre-MERCI era.
    Endo K; Koga M; Sakai N; Yamagami H; Furui E; Matsumoto Y; Shiokawa Y; Yoshimura S; Okada Y; Nakagawara J; Hyogo T; Hasegawa Y; Nagashima H; Fujinaka T; Hyodo A; Terada T; Toyoda K;
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):805-10. PubMed ID: 22721823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of full-dose intravenous recombinant tissue plasminogen activator followed by multimodal endovascular therapy for acute ischemic stroke.
    Nogueira RG; Yoo AJ; Masrur S; Batista LM; Hakimelahi R; Hirsch JA; Schwamm LH
    J Neurointerv Surg; 2013 Jul; 5(4):298-301. PubMed ID: 22705875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke.
    Mori E; Yoneda Y; Tabuchi M; Yoshida T; Ohkawa S; Ohsumi Y; Kitano K; Tsutsumi A; Yamadori A
    Neurology; 1992 May; 42(5):976-82. PubMed ID: 1579252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decrease in blood pressure after intravenous administration of urapidil during recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke.
    Bugnicourt JM; Duru C; Picard C; Godefroy O
    Clin Ther; 2008 Sep; 30(9):1675-80. PubMed ID: 18840373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign?
    Qureshi AI; Ezzeddine MA; Nasar A; Suri MF; Kirmani JF; Janjua N; Divani AA
    Neurology; 2006 Apr; 66(8):1171-4. PubMed ID: 16636232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator (rt-PA) therapy for acute cerebral infarction in a patient with ANCA-associated vasculitis].
    Akutagawa N; Sadashima S; Nakagaki H; Nagano S; Yoshimura T
    Rinsho Shinkeigaku; 2017 Aug; 57(8):454-456. PubMed ID: 28740062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
    Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
    Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the Clinical Efficacy of Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction.
    Wu T; Li P; Sun D
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7781-7786. PubMed ID: 32711658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [TCD monitoring during intravenous administration of recombinant tissue plasminogen activator].
    Aoki J; Iguchi Y; Kobayashi K; Sakai K; Shibazaki K; Sakamoto Y; Kimura K
    Rinsho Shinkeigaku; 2010 Aug; 50(8):547-55. PubMed ID: 20803963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
    Levine M; Hirsh J; Weitz J; Cruickshank M; Neemeh J; Turpie AG; Gent M
    Chest; 1990 Dec; 98(6):1473-9. PubMed ID: 2123152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designing thrombolytic agents: focus on safety and efficacy.
    Collen D
    Am J Cardiol; 1992 Jan; 69(2):71A-81A. PubMed ID: 1729881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endovascular treatment in proximal and intracranial carotid occlusion 9 hours after symptom onset.
    Jakubowska MM; Michels P; Müller-Jensen A; Leppien A; Eckert B
    Neuroradiology; 2008 Jul; 50(7):599-604. PubMed ID: 18443776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prospects of thrombolytic therapy for acute ischemic stroke].
    Nakashima T; Minematsu K
    Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.